[Uric acid balance in radiotherapy].
Administration of uricostatics within the scope of radiotherapeutic treatment is indicated in all cases of manifest primary gout; in cases of latent primary gout, uricostatics should be given especially after administration of high integral doses or in case of large tumors with distinct radiation sensitivity. The decision depends on the renal function, as an increased output of substances to be eliminated by urine may induce an attack of gout in cases of latent gout, or, otherwise, may cause renal lesions followed by acute uric acid nephropathy.
D000230:Adenocarcinoma / Q000532:radiotherapy; D006073:Gout / Q000150:complications; D006689:Hodgkin Disease / Q000532:radiotherapy; D006801:Humans; D007668:Kidney / Q000378:metabolism / Q000503:physiopathology; D007680:Kidney Neoplasms / Q000532:radiotherapy; D008297:Male; D011878:Radiotherapy; D011879:Radiotherapy Dosage; D014527:Uric Acid / Q000097:blood / Q000378:metabolism* / Q000652:urine; D014528:Uricosuric Agents / Q000627:therapeutic use; D001749:Urinary Bladder Neoplasms / Q000532:radiotherapy
D014528:Uricosuric Agents; D014527:Uric Acid
Uber die Harnsäurebilanz bei Strahlentherapie